Opinion|Videos|May 1, 2024

Diagnostic Tests for Kidney Cancer

Urologists provide an overview of diagnostic tests for patients with kidney cancer, highlighting lab tests, imaging, and considerations for biopsy.

Episodes in this series

Video 1 - "A Growing Incidence of Renal Masses"

EP. 1 A Growing Incidence of Renal Masses

Video 2 - "Diagnostic Tests for Kidney Cancer"

EP. 2 Diagnostic Tests for Kidney Cancer

EP. 3 Limitations of Conventional Imaging for Assessing Renal Masses

EP. 3 Limitations of Conventional Imaging for Assessing Renal Masses

Video 4 - "The Role of a Multidisciplinary Team in Managing Kidney Cancer"

EP. 4 The Role of a Multidisciplinary Team in Managing Kidney Cancer

Neal Shore, MD, FACS, and Brian M. Shuch, MD, experts on kidney cancer

EP. 5 Staging and Treatment Decisions for Kidney Cancer

Neal Shore, MD, FACS, and Brian M. Shuch, MD, experts on kidney cancer

EP. 6 Advances in Imaging for Kidney Cancer Diagnosis and Management

Neal Shore, MD, FACS, and Brian M. Shuch, MD, experts on kidney cancer

EP. 7 Overview of Clinical Trials for New Imaging Options for Kidney Cancer

Neal Shore, MD, FACS, and Brian M. Shuch, MD, experts on kidney cancer

EP. 8 Potential Impact of PET/CT Imaging on Improving Patient Care

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Related to this article

Behind the FDA approval of belzutifan plus lenvatinib in advanced ccRCC, with Robert Motzer, MD

September 30th, 2026

Behind the FDA approval of belzutifan plus lenvatinib in advanced ccRCC, with Robert Motzer, MD

Robert J. Motzer, MD, discusses the significance of the belzutifan plus lenvatinib approval, adverse event management with the combination, and the evolving role of HIF-2α inhibition in ccRCC.

FDA approves belzutifan plus lenvatinib for advanced clear cell renal cell carcinoma

September 24th, 2026

FDA approves belzutifan plus lenvatinib for advanced clear cell renal cell carcinoma

The approval is supported by data from the phase 3 LITESPARK-011 trial.

Trending on Urology Times

Rectal Spacers in Modern, Image-Guided Radiotherapy

FDA grants fast track designation to VIR-5500 for mCRPC

FDA grants 510(k) clearance to OpenFlo urinary catheter

Benchmarking AI Risk Estimates in Prostate Cancer Against STAR-CAP

Using AI Risk Estimates in Prostate Cancer Treatment Decisions